Skip to search formSkip to main contentSkip to account menu

SRPIN340

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Alternative splicing is a fundamental phenomenon to build protein diversity in health and diseases. Extra Domain A+ Fibronectin… 
2018
2018
.................................................................................................................................. viii RESUMO ........................................................................................................................................ ix Chapter 1: General Introduction .................................................................................................. 1 1. General Introduction ............................................................................................................. 2 1.1 Alternative splicing and its role in cancer ..................................................................... 2 1.2 SR Proteins and their roles in pre-mRNA splicing ......................................................... 4 1.3 SRPK and their oncogenic activity ................................................................................. 5 1.4 SRPK as drug target ....................................................................................................... 9 1.5 Aims of the thesis ........................................................................................................ 11 Chapter 2: Research Article I ...................................................................................................... 12 2. Research Article I: Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340) ................. 13 2.1 Abstract ....................................................................................................................... 14 2.2 Introduction ................................................................................................................ 15 2.3 Experimental procedures ............................................................................................ 16 2.3.1 Cell lines .............................................................................................................. 16 2.3.2 Isolation of PBMC from human blood ................................................................ 17 2.3.3 SRPK inhibitor synthesis ...................................................................................... 17 2.3.4 MTT cell viability assay ....................................................................................... 17 2.3.5 Flow cytometry assays ........................................................................................ 17 2.3.6 RT-PCR and RT-qPCR analysis ............................................................................. 17 2.3.7 Western blot analysis ......................................................................................... 18 2.3.8 Cloning, expression and purification procedures ............................................... 18 2.3.9 Fluorescence spectroscopy ................................................................................. 19 2.3.10 Computational analysis ..................................................................................... 19 2.3.11 Statistical analysis ............................................................................................. 20 2.4 Results ......................................................................................................................... 21 2.4.1 Expression of SRPK1 and SRPK2 in leukemia cells .............................................. 21 
2014
2014
Purpose AMD is a major cause of blindness. Current therapy aims to suppress VEGF levels in order to prevent CNV, which causes AMD… 
2013
2013
Purpose To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for…